Trial document

drksid header


Trial Description

start of 1:1-Block title


Effects of antihypertensive therapy on pregnancy outcome – An observational cohort study of the Pharmakovigilanz- und Beratungszentrum für Embryonaltoxikologie Berlin

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym


end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial


end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language

Hypertension is the most prevalent cardiovascular disease in pregnancy. The aim of the study is to confirm that there is no increased risk for congenital malformations or spontaneous abortions after first trimester exposure to antihypertensives.

end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

The objective of this study is to evaluate prospectively ascertained pregnancies of hypertensive women with antihypertensive therapy during the first trimester with respect to major malformations and spontaneous abortions. The following antihypertensives will be analysed:
methyldopa, angiotensin-converting enzyme-inhibitors (ACE-inhibitors), ARBs (AT1-antagonists) and calcium-channel-blockers. Exposed pregnancies will be compared to a control group of pregnant women without antihypertensive therapy. In case of an increased risk a secondary analysis will be performed comparing the group treated with the study medication (Methyldopa, ACE-I, ARBs or calcium-channel blockers) with a disease control group of hypertensive pregnant women with monotherapy of metoprolol or bisoprolol in the first trimester. The study is expected to improve risk assessment of antihypertensive therapy in the first trimester and to contribute to safety of drug treatment during pregnancy

end of 1:1-Block scientific synopsis
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00010502
  •   2016/05/20
  •   [---]*
  •   yes
  •   Approved
  •   EA1/107/16, Ethik-Kommission der Charité -Universitätsmedizin Berlin-
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  • [---]*
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   Q89.9 -  Congenital malformation, unspecified
  •   O03 -  Spontaneous abortion
  •   Congenital malformations and spontaneous abortions after antihypertensive therapy in the first trimester of pregnancy.
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  •   Study group: Antihypertensive treatment in first trimester
  •   Control group: No antihypertensive treatment in first trimester
  •   Disease control Group: Monotherapy with metoprolol or bisoprolol in first trimester
end of 1:N-Block interventions
start of 1:1-Block design


  •   Non-interventional
  •   Observational study
  •   Non-randomized controlled trial
  •   Blinded
  •   assessor, data analyst
  •   Other
  •   Prognosis
  •   Parallel
  •   N/A
  •   Yes
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

Risk for malformations and rate of spontaneous abortions

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome


end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   Germany
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

  • Medical Center 
end of 1:n-Block recruitment locations
start of 1:1-Block recruitment


  •   Actual
  •   2016/05/23
  •   5500
  •   Monocenter trial
  •   National
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Female
  •   no minimum age
  •   no maximum age
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

prospectively ascertained pregnancy

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

Exclusion of concomitant therapy with known teratogens or fetotoxic drugs: carbamazepine, lenalidomide, methotrexate,mycophenolate, phenobarbital, phenytoin, retinoids, thalidomide, topiramate, valproate, ARBs (AT1-antagonists)* and ACE-inhibitors*. In addition malignant diseases are defined as exclusion criterion.

Therapy with ARBs (AT1-antagonists) and ACE-inhibitors* in the first trimester is only possible in the corresponding study groups of these substances, but pregnancies with continued therapy after week 20 are excluded.

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses


end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • Bundesministerium für Gesundheit
    • 53123  Bonn
    • Germany
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact materialSupport
  • start of 1:1-Block address otherSupport
    • Bundesinstitut für Arzneimittel und Medizinprodukte
    • Kurt-Georg-Kiesinger-Allee 3
    • 53175  Bonn
    • Germany
    end of 1:1-Block address otherSupport
    start of 1:1-Block address contact otherSupport
    end of 1:1-Block address contact otherSupport
end of 1:n-Block material support
start of 1:1-Block state


  •   Recruiting ongoing
  •   [---]*
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

  •   Hoeltzenbein M, Beck E, Fietz AK, Wernicke J, Zinke S, Kayser A, Padberg S, Weber-Schoendorfer C, Meister R, Schaefer C. Pregnancy Outcome After First Trimester Use of Methyldopa: A Prospective Cohort Study. Hypertension. 2017;70:201-208.
end of 1:n-Block publications
* This entry means the parameter is not applicable or has not been set.
*** This entry means that data is not displayed due to insufficient data privacy clearing.